Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

292 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical and Economic Benefits of Lenzilumab Plus Standard of Care Compared with Standard of Care Alone for the Treatment of Hospitalized Patients with Coronavirus Disease 19 (COVID-19) from the Perspective of National Health Service England.
Kilcoyne A, Jordan E, Thomas K, Pepper AN, Zhou A, Chappell D, Amarapala M, Thériault RK, Thompson M. Kilcoyne A, et al. Among authors: chappell d. Clinicoecon Outcomes Res. 2022 Apr 14;14:231-247. doi: 10.2147/CEOR.S360741. eCollection 2022. Clinicoecon Outcomes Res. 2022. PMID: 35444434 Free PMC article.
Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with COVID-19 in the United States from the hospital perspective.
Kilcoyne A, Jordan E, Zhou A, Thomas K, Pepper AN, Chappell D, Amarapala M, Hughes A, Thompson M. Kilcoyne A, et al. Among authors: chappell d. J Med Econ. 2022 Jan-Dec;25(1):160-171. doi: 10.1080/13696998.2022.2030148. J Med Econ. 2022. PMID: 35037816 Free article.
C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 'LIVE-AIR' trial.
Temesgen Z, Kelley CF, Cerasoli F, Kilcoyne A, Chappell D, Durrant C, Ahmed O, Chappell G, Catterson V, Polk C, Badley A, Marconi VC; LIVE-AIR Study Group. Temesgen Z, et al. Among authors: chappell g, chappell d. Thorax. 2023 Jun;78(6):606-616. doi: 10.1136/thoraxjnl-2022-218744. Epub 2022 Jul 6. Thorax. 2023. PMID: 35793833 Free PMC article. Clinical Trial.
Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial.
Temesgen Z, Burger CD, Baker J, Polk C, Libertin CR, Kelley CF, Marconi VC, Orenstein R, Catterson VM, Aronstein WS, Durrant C, Chappell D, Ahmed O, Chappell G, Badley AD; LIVE-AIR Study Group. Temesgen Z, et al. Among authors: chappell g, chappell d. Lancet Respir Med. 2022 Mar;10(3):237-246. doi: 10.1016/S2213-2600(21)00494-X. Epub 2021 Dec 1. Lancet Respir Med. 2022. PMID: 34863332 Free PMC article. Clinical Trial.
GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study.
Temesgen Z, Assi M, Shweta FNU, Vergidis P, Rizza SA, Bauer PR, Pickering BW, Razonable RR, Libertin CR, Burger CD, Orenstein R, Vargas HE, Palraj R, Dababneh AS, Chappell G, Chappell D, Ahmed O, Sakemura R, Durrant C, Kenderian SS, Badley AD. Temesgen Z, et al. Among authors: chappell g, chappell d. Mayo Clin Proc. 2020 Nov;95(11):2382-2394. doi: 10.1016/j.mayocp.2020.08.038. Epub 2020 Sep 3. Mayo Clin Proc. 2020. PMID: 33153629 Free PMC article.
GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts.
Sterner RM, Sakemura R, Cox MJ, Yang N, Khadka RH, Forsman CL, Hansen MJ, Jin F, Ayasoufi K, Hefazi M, Schick KJ, Walters DK, Ahmed O, Chappell D, Sahmoud T, Durrant C, Nevala WK, Patnaik MM, Pease LR, Hedin KE, Kay NE, Johnson AJ, Kenderian SS. Sterner RM, et al. Among authors: chappell d. Blood. 2019 Feb 14;133(7):697-709. doi: 10.1182/blood-2018-10-881722. Epub 2018 Nov 21. Blood. 2019. PMID: 30463995 Free PMC article.
First Clinical Use of Lenzilumab to Neutralize GM-CSF in Patients with Severe COVID-19 Pneumonia.
Temesgen Z, Assi M, Vergidis P, Rizza SA, Bauer PR, Pickering BW, Razonable RR, Libertin CR, Burger CD, Orenstein R, Vargas HE, Varatharaj Palraj BR, Dababneh AS, Chappell G, Chappell D, Ahmed O, Sakemura R, Durrant C, Kenderian SS, Badley A. Temesgen Z, et al. Among authors: chappell g, chappell d. medRxiv [Preprint]. 2020 Jun 14:2020.06.08.20125369. doi: 10.1101/2020.06.08.20125369. medRxiv. 2020. PMID: 32587983 Free PMC article. Updated. Preprint.
GM-CSF disruption in CART cells modulates T cell activation and enhances CART cell anti-tumor activity.
Cox MJ, Manriquez Roman C, Tapper EE, Siegler EL, Chappell D, Durrant C, Ahmed O, Sinha S, Mwangi R, Scott NS, Hefazi M, Schick KJ, Horvei P, Ruff MW, Can I, Adada M, Bezerra E, Kankeu Fonkoua LA, Parikh SA, Kay NE, Sakemura R, Kenderian SS. Cox MJ, et al. Among authors: chappell d. Leukemia. 2022 Jun;36(6):1635-1645. doi: 10.1038/s41375-022-01572-7. Epub 2022 Apr 19. Leukemia. 2022. PMID: 35440691 Free PMC article.
T cell-tumor cell: a fatal interaction?
Chappell DB, Restifo NP. Chappell DB, et al. Cancer Immunol Immunother. 1998 Oct;47(2):65-71. doi: 10.1007/s002620050505. Cancer Immunol Immunother. 1998. PMID: 9769114 Free PMC article. Review.
292 results